https://scholars.lib.ntu.edu.tw/handle/123456789/581804
標題: | APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? | 作者: | Kanda T. Lau G.K.K. Wei L. Moriyama M. Yu M.-L. Chuang W.-L. Ibrahim A. Lesmana C.R.A. Sollano J. Kumar M. Jindal A. Sharma B.C. Hamid S.S. Dokmeci A.K. Mamun-Al-Mahtab, McCaughan G.W. Wasim J. Crawford D.H.G. JIA-HORNG KAO Yokosuka O. Sarin S.K. Omata M. |
關鍵字: | DAA; Guideline; HCV; Hemodialysis; Renal impairment; SVR | 公開日期: | 2019 | 出版社: | Springer | 卷: | 13 | 期: | 2 | 起(迄)頁: | 103-109 | 來源出版物: | Hepatology International | 摘要: | Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12?weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir for 8–16?weeks also results in high SVR rates in patients with all HCV GTs and stage 4 or 5 CKD. However, these regimens are contraindicated in the presence of advanced decompensated cirrhosis. Although sofosbuvir and/or ribavirin are not generally recommended for HCV-infected patients with severe renal impairment, sofosbuvir-based regimens may be appropriate for those with mild renal impairment. To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies. ? 2018, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058543693&doi=10.1007%2fs12072-018-9915-5&partnerID=40&md5=c8d87fcd2b636f488875cf4faf062fc5 https://scholars.lib.ntu.edu.tw/handle/123456789/581804 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-018-9915-5 | SDG/關鍵字: | asunaprevir; beclabuvir; boceprevir; daclatasvir; elbasvir; elbasvir plus grazoprevir; glecaprevir; glecaprevir plus pibrentasvir; grazoprevir; ledipasvir; ledipasvir plus sofosbuvir; ombitasvir; ombitasvir plus paritaprevir plus ritonavir; paritaprevir; pibrentasvir; ribavirin; simeprevir; sofosbuvir; telaprevir; velpatasvir; voxilaprevir; ABT-493; antivirus agent; benzimidazole derivative; benzofuran derivative; elbasvir-grazoprevir drug combination; imidazole derivative; pibrentasvir; quinoxaline derivative; sofosbuvir; sulfonamide; Article; clinical practice; disease classification; drug efficacy; drug safety; hemodialysis; hepatitis C; human; kidney failure; kidney graft; priority journal; sustained virologic response; chronic hepatitis C; chronic kidney failure; complication; drug combination; drug contraindication; genetics; genotype; Hepacivirus; practice guideline; Antiviral Agents; Benzimidazoles; Benzofurans; Contraindications, Drug; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。